23 Posts Not To Miss From SOHO2024

The twelfth annual meeting of the Society of Hematologic Oncology (SOHO 2024) was held from September 4-7, 2024 at the George R. Brown Convention Center in Houston, Texas.

Our team at OncoDaily has selected a few highlights from the SOHO2024 that you should not miss!

Yan Leyfman:

“Had an incredible time attending my first Society of Hematologic Oncology meeting and presenting our research! Grateful to SOHO for an enriching experience and the chance to connect with some of the brightest stars in oncology. Success is built on great mentorship— thank you, Dr. Chandler Park, M.D., F.A.C.P., for always believing in me!”

David Steensma:

“Great to see not-really-retired Mark Litzow, Mayo Clinic discussing the E1910 cooperative group trial in adult ALL, recently published NEJM, at SOHO24, showing benefit from adding immunotherapy in MRD-.

(Mark was an important mentor for me as a fellow and young faculty member.)

Aaron Logan:

“SOHO meeting growth over the years. Now ~2500 with 2000 in person. This is my first time coming and other than the heat and humidity in Houston, it’s great.”

Juan Rangel:

“I found Dr Graff’s talk highly relevant to our region, implementing a bispecific program into de oncology community practice.”

Mehmet Sevki Uyanik:

“INITIAL-1 trial: 3 cycles of Inotuzumab followed by Chemo consolidation in the Tx of Ph(-) B ALL.

3 year survival of older patients treated with

• Pediatric-based Chemo: 50% (Historic data, Gokbuket et al)
• INITIAL Trial: 73%

By Matthias Stelljes, MD.”

Karun Neupane:

“Early relapse is the new NDMM- patients with early relapse MM usually can have remission similar to or even longer than their first one, hence we should aim for deep response while treating early relapse MM.

Sagar Lonial on the wrap-up day of SOHO24.”

Fadi Haddad:

“CD7-CAR T-cells promosing for R/R T-cell ALL/LBK SOHO24.

• High responses and improved survival
• Transplant significantly decresed the risk of relapse.”

Roha Saeed Memon:

“Got to Houston late last night but guess what, we made it to SOHO24.

Meeting my senior, a great friend and mentor Charan Thej Reddy Vegivinti absolutely made my day. Thanks for a killer desi dinner at Kiran Verma.

Also made some really good friends!!”

Marah Alzubi:

“Was an honor to attend the plenary session on ‘BCL2 Inhibition in CLL: From Undruggable Target to Standard of Care’. Dr. John Seymour gave such an inspiring talk and I’ll be sharing my top three takeaways in the next tweet.

• Venetoclax is effective in indicing apoptosis even in TP53 mutated cells
• Venetoclax was approved relatively quickly highlighting the high effectivity of the drug and the bcl2 target
• MCL-1 overExpression can cause venetoclax resistance.”

Izel Okcu:

“I’m incredibly grateful and beyond excited to have received the SOHO Honorable Distinction Poster Award. Thank you to everyone who supported me throughout this journey!”

Ajay Major:

“For those of you at SOHO2024, check out our follow-up manuscript from last year’s Society of Hematologic Oncology on how we can better incorporate PROs into the hematologic oncology space to measure the tolerability of novel therapies.”

Kelly Meza:

“What an incredible start at SOHO24!

Such a valuable chance to engage with exceptional thought leaders and peers from around the globe. I was honored to share my research on ATLL, MF, and HLH.

Concluded with a stimulating discussion led by Christopher Flowers.”

Naveen Pemmaraju:

“Delighted to get to see and huge shout out to Rami komrokji world expert in MDS – at SOHO24 – a special thanks to Rami for his continued support and advocacy for our BPDCN and MPN fields!!!”

Mamtha Balla:

“I couldn’t believe how fast it happened! I’m thrilled to see myself on the poster at SOHO already, all thanks to SOHO for featuring me on the board!”

Jayastu Senapati:

“Happy to get the Second Place Poster Session Award at SOHO2024 on Venetoclax added to HyperCVAD-Nelarabine, Pegaspargase In T-cell Acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL), Phase 2 study.”

Lisa Palacios:

“Ran into some familiar MD Anderson Cancer Center faces at SOHO2024 on Day 1. Society of Hematologic Oncology President G Garcia-Manero with M. Silverstein, Navel Daver and Tapan Kadia.”

Jeff Lancet:

“Moffitt MDS world expert Rami Komrokji moderating MDS session at SOHO2024, novel targeted therapies effectively reducing transfusion dependence in MDS – including trials led and run at Moffitt!”

Parisa Aijaz:

“Here for a day full of learning and meeting leaders of the field.

SOHO2024 happy with how our posters turned out!

It was so lovely finally meeting you in person Nausheen Ahmed, USMIRC News.”

Mamtha Balla:

“I am incredibly grateful for the approval of my team research to be presented at SOHO2024. I am thrilled about the opportunity to showcase it at a poster presentation! I appreciate this chance!

Society of Hematologic Oncology, MD Anderson Cancer Center, Heme-Onc Fellowship Mentorship Empowerment, Heme-Onc Fellows Network, HemeOnc Today. Thanks Hagop Kantarjian, Guillermo Garcio Manero.”

Anand Patel:

“Had a great time at Society of Hematologic Oncology SOHO2024 presenting about challenging MPN scenarios!

I also learned a ton about anemia-directed therapies in myelofibrosis from Stephen Oh and JAK2m clonal hematopoiesis from Lachelle Dawn!”

Bilal Abid:

“Talk of the day: ‘Early versus late Chimeric antigen receptor (CAR)-T in Myeloma.’ No consensus reached but both sides up a notch with life qoutes, sports and music references! Just because you can do something doesn’t mean you should do it”

Nitin Jain:

“John Seymour giving Michael Keating plenary award lecture at SOHO24.

First patient ever treated with venetoclax previously called ABT-199 was in June 2011 in Australia with Seymour.

Amazing how this drug has changed the practice of leukemia care, especially Chronic Lymphocytic Leukemia (CLL) and Acute Myeloid Leukemia (AML).”

Kim Aldecoa:

“One of the best aspects of conferences: the chance to meet friends and like-minded individuals who share the same passion.”

For more details on SOHO2024, click here.